Increasing Teen Driving Safety, 54558-54559 [05-18321]
Download as PDF
<![CDATA[
54558
Federal Register / Vol. 70, No. 178 / Thursday, September 15, 2005 / Notices
Submission of Written Information
In general, individuals or
organizations wishing to provide
written information for consideration by
the Citizens’ Health Care Working
Group should submit information
electronically to
citizenshealth@ahrq.gov. The Working
Group invites submissions on those
topics to be addressed at the Working
Group business meetings listed above.
Since all electronic submissions will be
posted on the Working Group web site,
separate submissions by topic will
facilitate review of ideas submitted on
each topic by the Working Group and
the public.
Dated: September 1, 2005.
Carolyn M. Clancy,
Director.
[FR Doc. 05–18389 Filed 9–13–05; 9:47 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Notice of Meetings
In accordance with section 10(d) of
the Federal Advisory Committee Act as
amended (5 U.S.C., Appendix 2), the
Agency for Healthcare Research and
Quality (AHRQ) announces meetings of
scientific peer review groups. The
subcommittees listed below are part of
the Agency’s Health Services Research
Initial Review Group Committee.
The subcommittee meetings will be
closed to the public in accordance with
the Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications are to be reviewed and
discussed at these meetings. These
discussions are likely to involve
information concerning individuals
associated with the applications,
including assessments of their personal
qualifications to conduct their proposed
projects. This information is exempt
from mandatory disclosure under the
above-cited statutes.
1. Name of Subcommittee: Health
Care Research Training.
Date: September 22–23, 2005 (Open
from 8 a.m. to 8:15 a.m. on September
22 and closed for remainder of the
meeting).
2. Name of Subcommittee: Health
Research Dissemination and
Implementation.
Date: October 20–21, 2005 (Open from
8 a.m. to 8:15 a.m. on October 21 and
closed for remainder of the meeting).
VerDate Aug<18>2005
15:03 Sep 14, 2005
Jkt 205001
3. Name of Subcommittee: Health
Systems Research.
Date: October 20–21, 2005 (Open from
8 a.m. to 8:15 a.m. on October 21 and
closed for remainder of the meeting).
4. Name of Subcommittee: Health
Care Technology and Decision Sciences.
Date: October 27–28, 2005 (Open from
8 a.m. to 8:15 a.m. on October 27 and
closed for remainder of the meeting).
5. Name of Subcommittee: Health
Care Quality and Effectiveness
Research.
Date: October 27–28, 2005 (Open 8
a.m. to 8:15 a.m. on October 27 and
closed for remainder of the meeting).
All the meetings above will take place
at: Agency for Healthcare Research and
Quality, John Eisenberg Conference
Center, 540 Gaither Road, Rockville,
Maryland 20850.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the nonconfidential portions
of the meetings should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Suite 2000, Rockville,
Maryland 20850, Telephone (301) 427–
1554. Agenda items for these meetings
are subject to change as priorities
dictate.
Dated: September 1, 2005.
Carolyn M. Clancy,
Director.
[FR Doc. 05–18388 Filed 9–13–05; 9:47 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Program Announcement 04065–
Supplement]
Increasing Teen Driving Safety
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005
supplemental funds for a cooperative
agreement program to provide support
and assistance to the Society for
Advancement of Violence and Injury
Research (SAVIR), for the development
and implementation of an intervention
to encourage teen driver compliance
with (and parental endorsement of)
Graduated Driver Licensing restrictions
on drivers who have an intermediate
license—the group for which crash risk
is highest among all drivers.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
B. Eligible Applicant
Assistance will be provided to SAVIR.
SAVIR is being targeted because they
are uniquely qualified to carry out this
activity. This assistance will be
delivered as a supplement to Program
Announcement 04065. SAVIR was the
only recipient of this award and the
current supplement is consistent with
the scope of the original announcement.
Dr. Robert Foss, the Principal
Investigator, is a leading expert in the
field of Graduated Drivers Licensing
(GDL) interventions and has recently
conducted a similar study using the
same methodology. Currently, no other
individual is in a position to conduct
and evaluate an enhanced enforcement
intervention, which requires the
development of specific materials on
local GDL laws to inform police officers,
teens, and families about the
requirements and penalties for GDL
infractions. Dr. Foss has already
developed these tools and training
methods. The time it would take for
another investigator to accrue the
knowledge required for this task and set
up an intervention and evaluation plan
would set the date of completion back
considerably and possibly derail the
project. This work is critical to
supporting the research agenda and
CDC’s mission to reduce fatalities and
injuries to teens from motor vehicle
crashes. This activity is also
instrumental in carrying forward the
research-related goals of the Adolescent
Trailblazer team.
C. Funding
Approximately $231,000 is available
in FY 2005 to fund this award. It is
expected that the award will begin on
October 1, 2005 and will be made for a
12-month budget period with a project
period of up to two years. Funding
estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement contact:
Technical Information Management
Section, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta,
GA 30341–4146, Telephone—770–488–
2700.
For technical questions about this
program, contact: Arlene Greenspan,
Project Officer, CDC, National Center for
Injury Prevention and Control, 4770
Buford Highway NE., Mailstop K–63,
Atlanta, GA 30341, Telephone—770–
488–1279, fax—770–488–1317, e-mail—
aig0@cdc.gov.
E:\FR\FM\15SEN1.SGM
15SEN1
Federal Register / Vol. 70, No. 178 / Thursday, September 15, 2005 / Notices
Dated: September 9, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–18321 Filed 9–14–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Cardiovascular and Renal Drugs
Advisory Committee; Notice of Meeting
AGENCY:
ACTION:
Food and Drug Administration
[Docket No. 2004N–0486]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Experimental Study of Health Claims
on Food Packages
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Experimental Study of Health Claims
on Food Packages’’ has been approved
by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
In the
Federal Register of April 20, 2005 (70
FR 20568), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0565. The
approval expires on August 31, 2008. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
SUPPLEMENTARY INFORMATION:
Dated: September 7, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–18283 Filed 9–14–05; 8:45 am]
BILLING CODE 4160–01–S
VerDate Aug<18>2005
15:03 Sep 14, 2005
Jkt 205001
Food and Drug Administration,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Cardiovascular
and Renal Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 16, 2005, from 8 a.m.
to 5 p.m.
Location: Food and Drug
Administration, CDER Advisory
Committee Conference Room, rm. 1066,
5630 Fishers Lane, Rockville, MD.
Contact Person: Cathy Groupe, Center
for Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093), Rockville,
MD 20857, 301–827–7001, e-mail:
GroupeC@cder.fda.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512533. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will discuss
new drug application (NDA) 21–628,
proposed trade name CERTICAN
(everolimus) Tablets (0.25 milligrams
(mg), 0.50 mg, 0.75 mg, and 1.0 mg),
Novartis Pharmaceuticals Corporation,
for the proposed indication of
prophylaxis of rejection in heart
transplantation. The background
material will become available no later
than the day before the meeting and will
be posted on FDA’s Web site at https://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm. (Click on the year 2005
and scroll down to the heading
Cardiovascular and Renal Drugs
Advisory Committee.)
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by November 8, 2005. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Time allotted for each
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
54559
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before November 8, 2005, and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Beverly
O’Neil at 301–827–7001, at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 6, 2005.
Scott Gottlieb,
Deputy Commissioner for Policy.
[FR Doc. 05–18365 Filed 9–14–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Dental Products Panel of the Medical
Devices Advisory Committee; Notice of
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Dental Products
Panel of the Medical Devices Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on October 11, 2005, from 9:15
a.m. to 5:45 p.m., and on October 12,
2005, from 8 a.m. to 5 p.m.
Location: Hilton Washington DC
North/Gaithersburg, Ballroom Salons A
and B, 620 Perry Pkwy., Gaithersburg,
MD.
Contact Person: Michael E. Adjodha,
Center for Devices and Radiological
Health (HFZ–480), Food and Drug
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 70, Number 178 (Thursday, September 15, 2005)]
[Notices]
[Pages 54558-54559]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-18321]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement 04065-Supplement]
Increasing Teen Driving Safety
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
intent to fund fiscal year (FY) 2005 supplemental funds for a
cooperative agreement program to provide support and assistance to the
Society for Advancement of Violence and Injury Research (SAVIR), for
the development and implementation of an intervention to encourage teen
driver compliance with (and parental endorsement of) Graduated Driver
Licensing restrictions on drivers who have an intermediate license--the
group for which crash risk is highest among all drivers.
B. Eligible Applicant
Assistance will be provided to SAVIR. SAVIR is being targeted
because they are uniquely qualified to carry out this activity. This
assistance will be delivered as a supplement to Program Announcement
04065. SAVIR was the only recipient of this award and the current
supplement is consistent with the scope of the original announcement.
Dr. Robert Foss, the Principal Investigator, is a leading expert in the
field of Graduated Drivers Licensing (GDL) interventions and has
recently conducted a similar study using the same methodology.
Currently, no other individual is in a position to conduct and evaluate
an enhanced enforcement intervention, which requires the development of
specific materials on local GDL laws to inform police officers, teens,
and families about the requirements and penalties for GDL infractions.
Dr. Foss has already developed these tools and training methods. The
time it would take for another investigator to accrue the knowledge
required for this task and set up an intervention and evaluation plan
would set the date of completion back considerably and possibly derail
the project. This work is critical to supporting the research agenda
and CDC's mission to reduce fatalities and injuries to teens from motor
vehicle crashes. This activity is also instrumental in carrying forward
the research-related goals of the Adolescent Trailblazer team.
C. Funding
Approximately $231,000 is available in FY 2005 to fund this award.
It is expected that the award will begin on October 1, 2005 and will be
made for a 12-month budget period with a project period of up to two
years. Funding estimates may change.
D. Where To Obtain Additional Information
For general comments or questions about this announcement contact:
Technical Information Management Section, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone--770-
488-2700.
For technical questions about this program, contact: Arlene
Greenspan, Project Officer, CDC, National Center for Injury Prevention
and Control, 4770 Buford Highway NE., Mailstop K-63, Atlanta, GA 30341,
Telephone--770-488-1279, fax--770-488-1317, e-mail_aig0@cdc.gov.
[[Page 54559]]
Dated: September 9, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
[FR Doc. 05-18321 Filed 9-14-05; 8:45 am]
BILLING CODE 4163-18-P
